Reading ZVRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ZVRA free→Reading ZVRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ZVRA free→QuarterlyIQ Insights · ZVRA
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(0.5) + peer(0.2*4.1) + term(0.0) → 0.99% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Elevated risk of a next-quarter earnings miss: this name operates in a high-miss-rate industry and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
in 55 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On May 6, 2026, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the first quarter ended March 31, 2026, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Wednesday, May 6, 2026, at 4:30 p.m. ET. A copy of the press release is furnished as Exhibit 99.1…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On March 9, 2026, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the fourth quarter ended December 31, 2025, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Monday, March 9, 2026, at 4:30 p.m. ET. A copy of the press release is furnished as Exhibit…
Results of Operations and Financial Condition. On November 5, 2025, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the third quarter ended September 30, 2025, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Wednesday, November 5, 2025, at 4:30 p.m. ET. A copy of the press release is furnished a…
Results of Operations and Financial Condition. On August 12, 2025, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the second quarter ended June 30, 2025, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Tuesday, August 12, 2025, at 4:30 p.m. ET. A copy of the press release is furnished as Exhibi…
Results of Operations and Financial Condition . On May 13, 2025, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the first quarter ended March 31, 2025, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Tuesday, May 13, 2025, at 4:30 p.m. ET. A copy of the press release is furnished as Exhibit 99.…
Results of Operations and Financial Condition. On April 7, 2025, the Company issued a press release in relation to the Asset Sale, in which the Company announced that as of March 31, 2025, the Company’s cash, cash equivalents and investments were approximately $68.7 million. The press release is attached to this Current Report on Form 8-K as Exhibit 99.1. The information contained in this item, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section…
Results of Operations and Financial Condition . On March 11, 2025, Zevra Therapeutics, Inc., a Delaware corporation (the "Company" or "Zevra"), issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024, as well as information regarding a conference call and live audio webcast to discuss its financial results and corporate updates scheduled for Tuesday, March 11, 2025, at 4:30 p.m. ET. A copy of the press release is furnished as Exhi…